跨国企业与国内机构联合开发并不罕有,本刊之前报道过的沪亚从微星手中买走做到临床Ⅰ期的西达苯胺就是其中一例。如今,同是抗肿瘤药,萘莫柔比星却反其道而行之,在国外做完临床Ⅱ期被抛到中国找买主,对于中国企业来说,这是不是一个绝佳的机会?然而,卖方“非价高者得”的表态似乎证明,他们更看重国内企业继续研发的实力。 It is not uncommon for multinationals to jointly develop with domestic institutions. The case of Shanghai Daya, which was previously reported in this issue, was purchased from MSI as a clinical Phase I clinical trial. Today, the same anti-cancer drug, nafaroxacin actually do the opposite, done in the clinical phase Ⅱ was thrown into China to find buyers, for Chinese enterprises, this is not a great opportunity? However, the stance of the seller “overpriced ” seems to prove that they pay more attention to the strength of domestic enterprises to continue research and development.